Cefminox (sodium)

Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model^[1][2]. In Vitro:Cefminox sodium (Compound MT-141) (0.1-800 μg/mL) is more active against gram-negative and anaerobic bacteria than against gram-positive bacteria^[1].
Cefminox sodium (10-50 μM, 48 h) significantly inhibits the hypoxia-induced cell proliferation dose-dependently in primary pulmonary artery smooth muscle cells (PASMCs) through the enhancement of both IP and PPARγ activities^[2]. In Vivo:Cefminox sodium (Compound MT-141) (2-480 mg/kg, s.c., single dose) shows the highest efficacy against strains of Escherichia coli, Klebsiella pneumoniae, Salmonella enteritidis, Proteus morganii, Proteus rettgeri, Proteus vulgaris, Yersinia enterocolitica, Psudomonas cepacia, and Clostridium perfringens in female Slc:ddY mice model^[1].
Cefminox sodium (1-1000 mg/kg, s.c., single dose) gives dose-related serum levels in male Slc:ddY mice^[1].
Cefminox sodium (160-320 mg/kg/day, i.v., single dose) significantly decreases mean pulmonary artery pressure (mPAP) in male SD rats with hypoxia-induced pulmonary hypertension (HPH)^[2].